<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To investigate the pathophysiological role of thrombopoietin (TPO) in thrombopoiesis, we measured its serum levels in 15 healthy individuals, 84 patients with various <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> and 2 patients with liver <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> using an enzyme immunoassay procedure </plain></SENT>
<SENT sid="1" pm="."><plain>The TPO level was 0.84 +/- 0.40 f mol/ml in <z:mpath ids='MPATH_458'>normal</z:mpath> individuals </plain></SENT>
<SENT sid="2" pm="."><plain>TPO levels were considerably elevated in patients with <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> after intensification chemotherapy of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> in complete remission (postchemotherapy group; n = 18; 18.46 +/- 9.70 f mol/ml) </plain></SENT>
<SENT sid="3" pm="."><plain>When the data of <z:mpath ids='MPATH_458'>normal</z:mpath> individuals and the postchemotherapy group were combined, TPO levels were inversely correlated with the platelet count in this combined group </plain></SENT>
<SENT sid="4" pm="."><plain>We compared these data of <z:mpath ids='MPATH_458'>normal</z:mpath> individuals and the postchemotherapy group with various hematological <z:mp ids='MP_0002054'>disease states</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (n = 13; 16.03 +/- 9.44 f mol/ml), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n = 5; 10.36 +/- 5.57 f mol/ml), malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 6; 2.79 +/- 2.27 f mol/ml), <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (n = 3; 3.34 +/- 0.20 f mol/ml) and <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (n = 2; 1.71 +/- 3.91 f mol/ml), the relationship of serum TPO levels and platelet counts was almost the same as in the combined group with <z:mpath ids='MPATH_458'>normal</z:mpath> individuals and the postchemotherapy group </plain></SENT>
<SENT sid="6" pm="."><plain>However, the TPO levels were slightly higher in <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (n = 12; 1.99 +/- 1.47 f mol/ml) and lower in <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (n = 8; 2.27 +/- 1.25 f mol/ml), hypoplastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 3; 2.76 +/- 2.23 f mol/ml), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n = 2; 0.42 +/- 0.60 f mol/ml), liver <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> (n = 2; 1.50 +/- 0.92 f mol/ml) and <z:hpo ids='HP_0001973'>idiopathic thrombocytopenic purpura</z:hpo> (n = 12; 2.08 +/- 1.41 f mol/ml), when compared to the regression line for the combined group with <z:mpath ids='MPATH_458'>normal</z:mpath> individuals and postchemotherapy group </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that TPO might play an important role in regulation of the platelet count in <z:mpath ids='MPATH_458'>normal</z:mpath> and pathological conditions </plain></SENT>
</text></document>